Dr Chris Burns, the CEO of NOVONIX Limited (ASX:NVX), shares details on a significant supply agreement with Stellantis for synthetic graphite, a milestone for the North American battery market.
Copyright 2024 – Finance News Network
Source: Finance News Network
12 Oct 2023 - QX Resources (ASX:QXR) CEO Steve Promnitz discusses recent funding success and promising prospects for Liberty Lithium Brine Project.
Read More24 Mar 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses historical precedence for recovering from government spending, the possible rise of interest rates, labour market data, and investment strategies in this environment.
Read More16 Nov 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses excess cash in the global economy, inflation, growth and promising investment sectors.
Read More22 Jun 2023 - Lake Resources Limited (ASX:LKE) Managing Director David Dickson discusses the company's two-phase strategy.
Read More06 Sep 2021 - Rural Funds Group (ASX:RFF) General Manager - Investor Relations and Marketing James Powell presents on the group's FY21 results.
Read More27 Aug 2021 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes provides an update on sales and distribution for the company's Automated Plate Assessment System (APAS), which is used to read culture plates in laboratories.
Read More31 Mar 2021 - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q) CEO and Managing Director James Graham talks about progress with the company's lead anti-infective candidate Recce 327, its expanding portfolio of synthetic anti-infectives targeting viral pathogens and a broad range of bacteria, clinical trial results and priorities for 2021.
Read More03 Nov 2023 - Vital Metals (ASX:VML) Chairman Richard Crookes shares exclusive insights on Nechalacho, Rare Earth projects, and the company's strategic partnerships, offering a compelling overview of their journey and future prospects.
Read More09 Mar 2021 - Paragon Care Limited (ASX:PGC) CEO Phil Nicholl provides an update on the company's 1H21 results, discussing the increase in elective surgery and higher margin sales following COVID disruptions.
Read More26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More
